The Effect of Semaglutide on the Intestinal Flora in Obesity
ConditionObesity
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorBeijing Chao Yang Hospital
About this trial
For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.
Eligibility criteria
Qualifiers
18 to 60 years old;
BMI ≥ 30kg/m²;
At least one self-reported history of unsuccessful lifestyle weight loss;
Subjects who agree to participate in the project and sign the informed consent form.
Disqualifiers
Weight changes within 3 months prior to screening (self-reported) >5%;
Having received any drug treatment for obesity within the three months prior to screening;
The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes;
Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and/or other gastrointestinal motility drugs within 3 months prior to screening;
Trial design
Treatments tested in this trial
- Semaglutide Injection
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov